These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31631483)

  • 1. A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation.
    Kosaka T; Hongo H; Aimono E; Matsumoto K; Hayashida T; Mikami S; Nishihara H; Oya M
    Pathol Int; 2019 Dec; 69(12):715-720. PubMed ID: 31631483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel germline BRCA2 mutation in a Chinese patient with prostate cancer sensitive to platinum chemotherapy: a case report.
    Jiang L; Bai Z; Zhu S; Zhao T; Yang Y; Li Z; Chen D; Wu Z; Wang Y; Zhou F; Li Y
    BMC Urol; 2021 Aug; 21(1):114. PubMed ID: 34425813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
    Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
    BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors.
    Decker B; Karyadi DM; Davis BW; Karlins E; Tillmans LS; Stanford JL; Thibodeau SN; Ostrander EA
    Am J Hum Genet; 2016 May; 98(5):818-829. PubMed ID: 27087322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
    Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
    Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries.
    Abdi B; Basset N; Perrot E; Benderra MA; Khalil A; Oudard S; Blanchet P; Brureau L; Coulet F; Cussenot O; Cancel-Tassin G
    Prostate; 2022 Sep; 82(12):1196-1201. PubMed ID: 35652560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-emergent neuroendocrine prostate cancer with a germline
    Pandya D; Shah M; Kaplan F; Martino C; Levy G; Kazanjian M; Batter S; Martignetti J; Frank RC
    Cold Spring Harb Mol Case Stud; 2021 Feb; 7(1):. PubMed ID: 33608381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
    Petrovics G; Price DK; Lou H; Chen Y; Garland L; Bass S; Jones K; Kohaar I; Ali A; Ravindranath L; Young D; Cullen J; Dorsey TH; Sesterhenn IA; Brassell SA; Rosner IL; Ross D; Dahut W; Ambs S; Figg WD; Srivastava S; Dean M
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):406-410. PubMed ID: 30542053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.
    Castro E; Jugurnauth-Little S; Karlsson Q; Al-Shahrour F; Piñeiro-Yañez E; Van de Poll F; Leongamornlert D; Dadaev T; Govindasami K; Guy M; Eeles R; Kote-Jarai Z;
    Ann Oncol; 2015 Nov; 26(11):2293-300. PubMed ID: 26347108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prostate cancer with BRCA2 pathogenic mutation: a clinicopathological analysis].
    Wang DH; Yin WL; Pan XY; Zhang MN; Nie L; Chen XQ; Zeng H; Zhou Q; Chen N
    Zhonghua Bing Li Xue Za Zhi; 2024 Aug; 53(8):789-796. PubMed ID: 39103259
    [No Abstract]   [Full Text] [Related]  

  • 12. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
    Taylor RA; Fraser M; Livingstone J; Espiritu SM; Thorne H; Huang V; Lo W; Shiah YJ; Yamaguchi TN; Sliwinski A; Horsburgh S; Meng A; Heisler LE; Yu N; Yousif F; Papargiris M; Lawrence MG; Timms L; Murphy DG; Frydenberg M; Hopkins JF; Bolton D; Clouston D; McPherson JD; van der Kwast T; Boutros PC; Risbridger GP; Bristow RG
    Nat Commun; 2017 Jan; 8():13671. PubMed ID: 28067867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer.
    Kimura H; Mizuno K; Shiota M; Narita S; Terada N; Fujimoto N; Ogura K; Hatano S; Iwasaki Y; Hakozaki N; Ishitoya S; Sumiyoshi T; Goto T; Kobayashi T; Nakagawa H; Kamoto T; Eto M; Habuchi T; Ogawa O; Momozawa Y; Akamatsu S
    Br J Cancer; 2022 Nov; 127(9):1680-1690. PubMed ID: 35986085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline BLM mutations and metastatic prostate cancer.
    Ledet EM; Antonarakis ES; Isaacs WB; Lotan TL; Pritchard C; Sartor AO
    Prostate; 2020 Feb; 80(2):235-237. PubMed ID: 31816118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer.
    Lang SH; Swift SL; White H; Misso K; Kleijnen J; Quek RGW
    Int J Oncol; 2019 Sep; 55(3):597-616. PubMed ID: 31322208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients.
    Wu J; Wei Y; Pan J; Jin S; Gu W; Gan H; Zhu Y; Ye DW
    Int J Cancer; 2021 Feb; 148(3):673-681. PubMed ID: 33006389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
    Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
    BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.
    Lee BH
    Urol Oncol; 2017 Sep; 35(9):575-576. PubMed ID: 28789927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
    Castro E; Goh C; Olmos D; Saunders E; Leongamornlert D; Tymrakiewicz M; Mahmud N; Dadaev T; Govindasami K; Guy M; Sawyer E; Wilkinson R; Ardern-Jones A; Ellis S; Frost D; Peock S; Evans DG; Tischkowitz M; Cole T; Davidson R; Eccles D; Brewer C; Douglas F; Porteous ME; Donaldson A; Dorkins H; Izatt L; Cook J; Hodgson S; Kennedy MJ; Side LE; Eason J; Murray A; Antoniou AC; Easton DF; Kote-Jarai Z; Eeles R
    J Clin Oncol; 2013 May; 31(14):1748-57. PubMed ID: 23569316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.